FPCG
NKTR icon

Fort Pitt Capital Group’s Nektar Therapeutics NKTR Stock Holding History

Fort Pitt Capital Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-167
Closed -$43K – 265
2020
Q4 		$43K Buy
+167
New +$43.2K ﹤0.01% 202

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Fort Pitt Capital Group's NKTR Position: Q1 2021 in Review

Fort Pitt Capital Group sold out of Nektar Therapeutics (NKTR) in Q1 2021, closing a stake of 167 shares — an estimated $43K sold.

Fort Pitt Capital Group first reported a position in NKTR in Q4 2020 and held it in 1 quarter. The position peaked at $43K in Q4 2020. 236 funds tracked by Wall St. Rank hold NKTR as of Q1 2021.

  • Fort Pitt Capital Group reported no remaining Nektar Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Fort Pitt Capital Group sold 167 Nektar Therapeutics shares in Q1 2021, an estimated $43K.
  • Fort Pitt Capital Group first reported a position in Nektar Therapeutics in Q4 2020 and held it in 1 quarter.
  • Fort Pitt Capital Group's Nektar Therapeutics position peaked at $43K in Q4 2020.
  • 236 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2021.

Based on Fort Pitt Capital Group's 13F filing for Q1 2021, filed 16 Apr 2021.